The global nipah virus (NiV) infection testing market is poised for significant growth, with projections indicating a market value of USD 3,277.49 million by 2033, up from USD 1,974.17 million in 2023. The market is expected to expand at a CAGR of 5.2% during the forecast period from 2023 to 2033, according to industry insights.
The demand for accurate and timely testing solutions is being fueled by the urgent need to address the public health challenges posed by Nipah virus outbreaks. Early detection plays a pivotal role in curbing the spread of the virus, enabling swift medical intervention and the implementation of effective containment strategies.
Key Growth Drivers:
- Rising Awareness and Preparedness: Governments and healthcare organizations are increasing their investments in diagnostic tools to manage potential outbreaks efficiently.
- Technological Advancements: Innovations in diagnostic methodologies, such as molecular testing and rapid point-of-care tests, are driving adoption rates globally.
- Global Health Initiatives: Partnerships among governments, non-profits, and private entities are fostering the development of accessible testing solutions, especially in high-risk regions.
Historical Market Performance
Between 2018 and 2022, the Nipah virus (NiV) infection testing market grew at a CAGR of 3.1%, reflecting the steady adoption of diagnostic solutions during the historical period. The forecasted growth indicates a substantial acceleration as global health concerns surrounding infectious diseases intensify.
Key Takeaways from the Market Study:
- The Nipah virus (NiV) infection testing market is expected to grow at a value of 5.2% CAGR in the forecast period 2023 to 2033
- By end user, hospitals are expected to possess 40% market share for Nipah virus (NiV) infection testing market in 2023.
- Asia Pacific is expected to possess 45% market share for Nipah virus (NiV) infection testing market in 2023.
- Middle East and Africa is expected to possess 39% market share for Nipah virus (NiV) infection testing market in 2023.
“The NiV infection testing market provides several benefits to the medical community and the general public. It enables healthcare providers to identify and treat infected individuals quickly and accurately. This helps reduce the spread of the virus and possible complications of the infection.” states an FMI analyst
Heightened Demand for Market Data: Our Full Report Provides Extensive Trend Analysis!
Competitive Landscape:
Key players in the Nipah virus (NiV) infection testing market are Aurobindo, Minapharm, Roche, Lupin Ltd, Siegfried, Vivacure, Starlake Bioscience, Xaretto, Liferiver, MyBioSource, Krishgen Biosystems
- Aurobindo has developed a rapid diagnostic test for NiV, allowing clinicians to quickly detect the presence of the virus. Additionally, Aurobindo has used its expertise in the field of immunoassay and ELISA development to create an antibody test for NiV.
- In July 2020, Roche launched the cobas® NiV/HEV Assay. This test is a qualitative in-vitro diagnostic assay that detects NiV and HEV nucleic acid from human specimens and provides results in just under two hours.
Key Segments Profiled in the Nipah Virus (NiV) Infection Testing Industry Survey:
Test Type:
- RT PCR based kits
- ELISA Kits
End User:
- Hospitals
- Research Labs
- Diagnostic Centres
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
